Market Exclusive

CAREDX, INC. (NASDAQ:CDNA) Files An 8-K Results of Operations and Financial Condition

CAREDX, INC. (NASDAQ:CDNA) Files An 8-K Results of Operations and Financial Condition

Item2.02 Results of Operations and Financial Condition.

On April21, 2017, CareDx, Inc. (the Company) issued a press
release announcing its financial results for the quarter and year
ended December31, 2016. A copy of the press release is attached
hereto as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item2.02, including the press release
attached hereto as Exhibit 99.1, is intended to be furnished
under Item2.02 and Item9.01 of Form 8-K and shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.

Item9.01. Financial Statements and Exhibits.

(d) Exhibits.

ExhibitNo. Description
99.1 Press Release issued by CareDx, Inc. dated April 21, 2017.

About CAREDX, INC. (NASDAQ:CDNA)
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients. CAREDX, INC. (NASDAQ:CDNA) Recent Trading Information
CAREDX, INC. (NASDAQ:CDNA) closed its last trading session up +0.05 at 1.00 with 103,032 shares trading hands.

Exit mobile version